Newborn Screening Test: What Parents Need to Know

The newborn screening test is a group of simple checks performed shortly after birth to find serious but rare health conditions early, often before your baby shows any signs or symptoms, so that treatment or special care can begin right away and protect your baby's long-term health.

The acylcarnitine newborn screening is a blood test that checks for certain rare inherited metabolic disorders. These disorders affect how the body converts food into energy, particularly how it breaks down fatty acids. The test measures levels of different acylcarnitines, which are substances that help transport fatty acids into cells where they can be used for energy.

The blood test is usually done before your baby leaves the hospital, most often between 24 and 48 hours after birth. A health care provider gently pricks your baby's heel and places a few drops of blood on a special filter paper card. Screening may also include a hearing check and a painless pulse oximetry reading on the skin.

A healthcare provider will prick your baby's heel to collect a few drops of blood. This is usually done 24-48 hours after birth, often before your baby leaves the hospital. The blood is placed on a special filter paper and sent to a laboratory for analysis. The test is part of the routine newborn screening panel and is generally safe with minimal discomfort for your baby.

Screening can detect many serious conditions, including phenylketonuria (PKU), congenital hypothyroidism, galactosemia, cystic fibrosis, sickle cell disease, congenital adrenal hyperplasia, and certain heart and hearing problems. The exact panel of conditions varies from state to state.

This screening can detect several metabolic disorders including medium-chain acyl-CoA dehydrogenase deficiency (MCAD), short-chain acyl-CoA dehydrogenase deficiency (SCAD), multiple acyl-CoA dehydrogenase deficiency (MADD), and various organic acidemias. These conditions are genetic and are usually inherited when both parents carry a gene mutation.

Most babies receive normal results, which means no conditions were found. If a result falls outside the normal range, it does not necessarily mean your baby has a condition; it means additional testing is needed. Your baby's doctor will contact you, explain the findings, and arrange follow-up testing to confirm or rule out a diagnosis.

If the screening shows abnormal acylcarnitine levels, it does not automatically mean your baby has a disorder. Abnormal results indicate that additional diagnostic testing is needed. Your healthcare provider will contact you if follow-up testing is required. It's important to remember that early detection through newborn screening allows for early intervention, which can prevent serious health complications.

Yes. Many of the conditions found through newborn screening can be treated, and starting treatment early often prevents serious health problems. Depending on the specific diagnosis, treatment may include a special diet, medication, hormone replacement, supplements, surgery, or ongoing monitoring by a team of specialists.

Yes, if a metabolic disorder is confirmed, treatment is available. Treatment typically includes a special diet, medications, and careful management of fasting periods. With early detection and proper treatment, many children with these disorders can live healthy lives. Your doctor will refer you to a metabolic specialist who will create a personalized treatment plan for your baby.